In this study, both Western blotting and IHC analyses revealed higher levels of IL-23 expression in tumors from chemoresistant CRC patients as compared to patients with chemosensitive disease, in line with prior findings (Figures 4C and 5B). This evidence concerns the gene IL37 and colorectal carcinoma.